Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Linggui Yangyuan Paste is a Traditional Chinese Medicine (TCM) formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is primarily investigated for the treatment of male infertility, specifically targeting conditions such as asthenozoospermia (reduced sperm motility) and oligoasthenozoospermia (reduced sperm count and motility). As a TCM "paste" (Gao), it is a concentrated herbal extract intended to tonify the kidneys and improve reproductive health. The drug is currently being evaluated in multicenter, double-blind, randomized controlled trials to assess its efficacy in improving sperm parameters and its overall safety profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Linggui Yangyuan Paste.